Synopsis: The bank’s headline profit took a hit from a one-time litigation provision, but 30 of 40 analysts tracked by Bloomberg are still calling it a ‘Buy’, and the core numbers explain why. The stock fell 18% in 2026 . Furthermore, mixed Q1 FY27 results showed margin pressure and an exceptional provision alongside healthy loan growth.
The company’s Q1 FY27 results came in mixed: healthy loan growth and stable asset quality on one side, margin pressure and a large exceptional provision on the other. The provision alone was big enough to swing headline profit meaningfully, which is why most of the brokerage commentary this weekend has focused on separating the one-off from the underlying run rate.
With a market capitalisation of roughly Rs. 1,26,638.94 crore, Bank of Baroda shares opened on Tuesday at Rs.242.80, down 0.49 percent from the previous close of Rs. 244. It is trading at a P/E of 7.13.
What’s the news?
Standalone net profit fell sharply after the bank set aside Rs. 5,680 crore towards settling the NMC Group litigation. Strip that out, and adjusted net profit was Rs. 5,528 crore, a very different picture from the headline number and the one that matters more for judging the underlying business. This is the kind of provision that shows up once, gets fully expensed in a single quarter, and then disappears from the P&L going forward, which is exactly why brokerages spent more time explaining it away than reacting to it.
Net interest margin slipped to 2.77 percent, down from 2.89 percent both a quarter ago and a year ago. Margin pressure isn’t new here, but it’s not easing either, and a decline that shows up on both the sequential and annual comparison is harder to explain away as a one-off base effect.
Brokerage reaction
Every brokerage cut its target price. Almost none of them changed their call, which is itself worth noting a round of target cuts without a single downgrade usually means analysts see the quarter’s weak spots as temporary rather than structural.
Citi kept its Buy rating and lowered the target to Rs. 310 from Rs. 340, pointing to a core return on assets of 1.10 percent once the one-off item is excluded, helped along by low credit costs, treasury gains and tax refund interest. It did trim FY27 and FY28 earnings estimates by 28 per cent and 2 per cent to account for the provision and softer fee income. The bigger cut to FY27 reflects the immediate hit, while the smaller FY28 revision suggests Citi doesn’t expect the NMC charge to have much lasting effect on earnings power two years out.
Macquarie held its buy call at a Rs. 310 target, called the operating performance steady, and is pencilling in 13 percent average loan growth over FY27-28. That growth number is doing a lot of work in Macquarie’s thesis it’s essentially the offset to the margin compression, the bet being that a bigger loan book at a slightly thinner margin still nets out to earnings growth.
JPMorgan stayed Overweight at Rs. 315, saying the valuation still backs a constructive view, without dwelling much on the operational softness. HSBC is the one holdout, a Hold at Rs. 276, on the view that return on assets could stay under 1 percent through FY28-29 and cap how much re-rating is possible. It’s the most conservative estimate of the group by some distance, both on rating and price target.
Across all 40 analysts tracking the stock, 30 say Buy, seven say Hold, three say Sell. That split has barely budged despite every target coming down, which tells you the consensus view hasn’t really changed after this result it’s mostly just recalibrating for the size of the one-off charge.
Why the NMC provision matters, and why it might not
The NMC Group litigation dates back to the healthcare conglomerate’s high-profile collapse, and Indian lenders with exposure have been working through recoveries and settlements for years now. A Rs. 5,680 crore provision is large in absolute terms, but the way brokerages have treated it, cleanly separating it from core earnings and mostly leaving ratings untouched, suggests the Street views this as closure on a known legacy exposure rather than a new problem surfacing. That distinction matters a lot for how the stock should be valued from here: a bank taking a big one-time hit to draw a line under an old litigation is a fundamentally different story from a bank whose provisioning needs keep growing quarter after quarter.
Seeing the Valuation Closely
The gap between reported and adjusted profit is wide enough that the headline number is genuinely misleading here. Rs. 5,680 crore is not a rounding error, and anyone reading this quarter’s reported EPS as a run-rate number is going to understate what the bank is actually earning by a fair margin.
The margin story worries me more, honestly. NIM is down both sequentially and year-on-year now, which is a trend, not a one-quarter blip. HSBC’s Hold from a brokerage that otherwise isn’t out of step with the Street is worth more attention. If loan growth doesn’t pick up the slack, Macquarie’s 13 percent volume number is carrying most of the earnings story on its own. It’s also worth asking what happens to that loan growth assumption if credit costs, currently described as benign, start normalising upward from here. PSU banks in general have benefited from a multi-year cycle of clean-up and low provisioning; that tailwind doesn’t run forever.
And on valuation: the highest target, Rs. 315, implies close to 30 percent upside from Monday’s close. That’s a big re-rating ask for a stock that’s already down 18 percent this year. Whether it happens really comes down to one thing is the NMC provision truly a one-off, or is this the first of a few legacy issues the bank still has to work through. The stock’s underperformance in 2026 relative to where brokerage targets sit suggests the market has been more cautious than analysts on exactly this question.
What to watch
The 1.10 percent core RoA, adjusted for the exceptional charge, is the number that matters most here and the one most likely to get buried under headline profit commentary. Keep an eye on NIM over the next couple of quarters. Another leg down undercuts the loan-growth thesis brokerages are betting on. A stabilisation would make the current 18 percent correction look more like an overreaction than a warning sign.
Beyond that, watch for any further disclosure on litigation-related exposures in coming quarters. If this NMC settlement turns out to be a genuinely isolated event, the valuation gap between the stock’s current price and where brokerages have it targeted starts to look like an opportunity. If instead it turns out to be one of several legacy issues still working through the system, the market’s caution this year will look better justified than the Street’s collective Buy rating does right now.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
